Results of a 2021 French National Survey on Management of Patients with Advanced Stage Epithelial Ovarian Cancer - Institut Gustave Roussy Accéder directement au contenu
Article Dans Une Revue Journal of Clinical Medicine Année : 2021

Results of a 2021 French National Survey on Management of Patients with Advanced Stage Epithelial Ovarian Cancer

Leonor Drouin
Benedetta Guani
  • Fonction : Auteur
  • PersonId : 1138941
Henri Azaïs
  • Fonction : Auteur
  • PersonId : 1093046
Pierre-Adrien Bolze
  • Fonction : Auteur
  • PersonId : 1077593
Yohann Dabi
  • Fonction : Auteur
  • PersonId : 1085062
Claire Sanson
  • Fonction : Auteur
  • PersonId : 1116816
François Zaccarini
  • Fonction : Auteur
  • PersonId : 1138945
Fabrice Lécuru
  • Fonction : Auteur
  • PersonId : 1100985
Fréderic Guyon
  • Fonction : Auteur
  • PersonId : 1116817
Cherif Akladios
  • Fonction : Auteur
  • PersonId : 1085063
Sofiane Bendifallah
  • Fonction : Auteur
  • PersonId : 1077592
Elise Deluche
  • Fonction : Auteur
  • PersonId : 1042765

Résumé

Background: The aim of this study was to assess current French practices in the management of patients with advanced epithelial ovarian cancer. Method: a 58-question electronic survey was distributed anonymously to the members of the SFOG (French Society of Gynaecological Oncology), GINECO-ARCAGY (National Investigators Group for Ovarian and Breast Cancer Studies in France) and FRANCOGYN (French research group in oncological and gynaecological surgery). Initial diagnostic workup and staging, pathological data, surgical data, treatments and follow-up strategies were assessed. Results: a total of 107 participants responded to emailed surveys. Most of the respondents were obstetrician-gynaecologists (37.4%), surgical oncologists (34.6%) and medical oncologists (17.8%). According to most (76.8%) participants, less than 50% of patients were eligible for primary debulking surgery (PDS). The LION study criteria were applied in 69.5% of cases during PDS and 39% after chemotherapy. The timing of BRCA testing was very heterogeneous and ranged from 1 to 6 months. The use of bevacizumab as an adjuvant schedule was lower in cases of no residual disease (for 54.5% of respondents) compared to cases of residual disease (for 63.6% of respondents). In cases of BRCA1-2 mutations, olaparib was given by 75.8–84.8% of respondents, whereas niraparib was given in cases of BRCA wild-type diseases. Conclusion: this survey provides an extensive and a unique review of current French practices in the management of patients with advanced epithelial ovarian cancer in 2021.
Fichier principal
Vignette du fichier
jcm-10-04829-v2.pdf (2.17 Mo) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03430300 , version 1 (16-11-2021)

Identifiants

Citer

Leonor Drouin, Benedetta Guani, Vincent Balaya, Henri Azaïs, Sarah Betrian, et al.. Results of a 2021 French National Survey on Management of Patients with Advanced Stage Epithelial Ovarian Cancer. Journal of Clinical Medicine, 2021, 10 (21), pp.4829. ⟨10.3390/jcm10214829⟩. ⟨hal-03430300⟩
75 Consultations
31 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More